Letters to the Editor

Short-term emicizumab in patients with acquired hemophilia A

Department of Hemostasis and Thrombosis, University Hospitals Leuven, Belgium; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven
Division of Hematology, Hemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium All authors are members of ERN-EuroBloodNet
Department of Hemostasis and Thrombosis, University Hospitals Leuven, Belgium; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven
Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven
Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven
Department of Hemostasis and Thrombosis, University Hospitals Leuven, Belgium; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven
Division of Hematology, Hemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium All authors are members of ERN-EuroBloodNet
Department of Hemostasis and Thrombosis, University Hospitals Leuven, Belgium; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, KU Leuven, Belgium; Division of Hematology, Hemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium All authors are members of ERN-EuroBloodNet
Haematologica Early view Jul 16, 2026 https://doi.org/10.3324/haematol.2026.301011